Latest Period
Q1 2026
Security Snapshot
Caris Life Sciences, Inc. - Common Stock, par value $0.001 per share (CAI) Institutional Ownership
CUSIP: 142152107
13F Institutional Holders and Ownership History from Q2 2025 to Q1 2026
Institutions Reporting
199
Shares (Excl. Options)
156,665,747
Price
$17.88
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- CAI on Nasdaq
- Shares outstanding
- 282,066,647
- Price per share
- $17.77
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 156,665,747
- Total reported value
- $2,797,619,919
- % of total 13F portfolios
- 0.02%
- Share change
- +3,437,743
- Value change
- -$13,710,474
- Number of holders
- 199
- Price from insider filings
- $17.77
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- CAI - Caris Life Sciences, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 142152107.
- 199 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 184 to 199 between Q4 2025 and Q1 2026.
- Reported value moved from $3,916,731,528 to $2,797,619,919.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 199 institutions filings for Q1 2026.
Security key
142152107
Latest holder period
Q1 2026
13F holders
199
13D/G owners
5
CIK / CUSIP context first
Open Q1 2026 holders
CAI full holder history
Caris Life Sciences, Inc. SEC filings
Caris Life Sciences, Inc. company facts
Caris Life Sciences, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 142152107:
Significant Owners of Caris Life Sciences, Inc. - Common Stock, par value $0.001 per share (CAI) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| HALBERT DAVID D | 44% | $3,311,265,907 | 124,906,296 | David D. Halbert | 30 Jun 2025 | |||
| FMR LLC | 11% | +116% | $547,689,677 | +$294,800,519 | 30,631,585 | +117% | FMR LLC | 31 Mar 2026 |
| J H Whitney VI L P | 6.5% | -11% | $329,531,901 | -$36,100,000 | 18,256,615 | -9.9% | J H Whitney VI L P | 31 Mar 2026 |
| TSSP Sub-Fund HoldCo LLC | 5.1% | -26% | $259,656,452 | -$90,250,000 | 14,385,399 | -26% | Alan Waxman | 31 Mar 2026 |
| RIVERVIEW GROUP LLC | 1.3% | 3,583,100 | Millennium Management LLC | 17 Jun 2025 |
As of 31 Mar 2026, 199 institutional investors reported holding 156,665,747 shares of Caris Life Sciences, Inc. - Common Stock, par value $0.001 per share (CAI). This represents 56% of the company’s total 282,066,647 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Caris Life Sciences, Inc. - Common Stock, par value $0.001 per share (CAI) together control 49% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 11% | 30,785,585 | +117% | 0.03% | $550,446,260 |
| J. H. Whitney Equity Partners VI, LLC | 6.5% | 18,256,615 | -9.9% | 100% | $326,428,276 |
| Sixth Street Partners Management Company, L.P. | 5.1% | 14,385,399 | -26% | 36% | $257,210,934 |
| COATUE MANAGEMENT LLC | 3.5% | 9,819,992 | 0% | 0.6% | $175,581,457 |
| BRAIDWELL LP | 2.8% | 8,009,447 | +2.5% | 4.8% | $143,208,912 |
| PointState Capital LP | 2.6% | 7,360,446 | +9.6% | 3.1% | $131,604,774 |
| T. Rowe Price Investment Management, Inc. | 2% | 5,588,257 | -39% | 0.07% | $99,919,000 |
| BlackRock, Inc. | 1.7% | 4,857,112 | +105% | 0% | $86,845,162 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.5% | 4,371,771 | -9.4% | 0.01% | $78,168,000 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.3% | 3,758,462 | 0% | 0% | $67,201,301 |
| NEUBERGER BERMAN GROUP LLC | 1.3% | 3,590,586 | -5.5% | 0.05% | $64,199,677 |
| JPMORGAN CHASE & CO | 1.2% | 3,460,215 | +42% | 0% | $58,304,631 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.2% | 3,329,021 | 0% | 0% | $59,522,895 |
| ORBIMED ADVISORS LLC | 1% | 2,806,811 | -9.9% | 1.1% | $50,185,781 |
| UBS Group AG | 0.97% | 2,745,811 | +26% | 0.01% | $49,095,101 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 0.81% | 2,289,602 | +405139% | 0.16% | $40,938,083 |
| Duquesne Family Office LLC | 0.67% | 1,894,450 | 1.2% | $33,873,000 | |
| BNP PARIBAS FINANCIAL MARKETS | 0.57% | 1,614,286 | 0% | 0.02% | $28,863,434 |
| Clearbridge Investments, LLC | 0.55% | 1,551,774 | +9.6% | 0.02% | $27,745,714 |
| FIL Ltd | 0.55% | 1,546,091 | +38% | 0.02% | $27,644,107 |
| MILLENNIUM MANAGEMENT LLC | 0.54% | 1,527,756 | -58% | 0.02% | $27,316,277 |
| CANADA PENSION PLAN INVESTMENT BOARD | 0.47% | 1,322,752 | -9.7% | 0.02% | $23,650,806 |
| Invesco Ltd. | 0.43% | 1,222,278 | +18% | 0% | $21,854,331 |
| Champlain Investment Partners, LLC | 0.43% | 1,207,963 | +29% | 0.27% | $21,598,378 |
| Capital World Investors | 0.42% | 1,180,173 | 0% | $21,101,493 |
Institutional Holders of Caris Life Sciences, Inc. - Common Stock, par value $0.001 per share (CAI) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 156,665,747 | $2,797,619,919 | -$13,710,474 | $17.88 | 199 |
| 2025 Q4 | 145,171,924 | $3,916,731,528 | +$281,575,305 | $26.98 | 184 |
| 2025 Q3 | 113,389,372 | $3,407,348,453 | +$143,025,542 | $30.25 | 137 |
| 2025 Q2 | 109,280,872 | $2,919,429,193 | +$2,917,131,273 | $26.72 | 115 |